DUPIXENT® (dupilumab injection) is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

Request a Field Representative Visit

Connect with a DUPIXENT® Field Representative to get answers to any product-related questions.

DRI12544, QUEST and VENTURE clinical trials (in adults and adolescents aged ≥12 years)

For patients aged 6+ years with severe asthma with a type 2/eosinophilic phenotype or OCS-dependent asthma

DUPIXENT box and syringe.

The Freedom Support Program:

A program defined by the service we provide

Personalized support. Specialized care. Passionate team.

* Comparative clinical significance is unknown.
† The DUPIXENT® pre-filled pen is only for use in adults and adolescents aged 12 years and older.


Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023


Innovative Medicines Canada logo PAAB logo